clinical trial · NCT04953884
Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of Age
Octapharma·phase3·completed·n = 12
Von Willebrand DiseaseWilate
brief summary
The WIL-33 study aimed to determine the efficacy, pharmacokinetics, immunogenicity and safety of wilate as routine prophylaxis in up to 12 paediatric patients (eight evaluable) with severe von Willebrand Disease VWD (defined as screening von Willebrand factor ristocetin cofactor activity \[VWF:RCo\] \<20%) under the age of 6 years, over a period of 12 months.
started
Sep 22, 2021
primary completion
Dec 16, 2024
completion
Dec 16, 2024
last updated
Feb 20, 2026
official title
Clinical Study to Investigate the Efficacy, Pharmacokinetics, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease Patients Under the Age of 6 Years
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol